ClinicalTrials.gg
WithdrawnNCT02206919Updated Nov 19, 2026

Magnetic Resonance Imaging of Vascular Function

An observational study in Diabetes and Endothelial Dysfunction, sponsored by Sunnybrook Health Sciences Centre. Withdrawn at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sunnybrook Health Sciences Centre · Observational

How we know

Why this study was withdrawn
funding issue
Updated Nov 19, 2026Now WithdrawnPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 493 studies in Diabetes Mellitus with a site in Canada — 39 open to participants now, 55 under way, 5 of them phase 3. Diabetes Mellitus · Canada.

Enrollment
89th of 92
0 · median 100
Started
2014
with 23 others
Observational
92 of 493
14 open now
Registered
259th of 493
by date

Among the 493 studies in Diabetes Mellitus with a site in Canada, this one is the 89th largest by enrollment of the 92 observational ones that give a count, is one of 24 that started in 2014, is one of 92 observational ones, and was the 259th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

39 of the 493 studies in Diabetes Mellitus with a site in Canada are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 493 studies in Diabetes Mellitus with a site in Canada, or all of them as a file.
02

Study summary

A major function of blood vessels is to control blood flow by dilating or constricting depending on the demand. Vascular dysfunction is a state in which blood vessels fail to carry out its normal roles such as regulating blood flow. Diabetes is a risk factor for vascular dysfunction. Dysfunction may involve the smaller and/or larger blood vessels. Failure in the ability of large (conduit) blood vessels to control blood flow may be an early feature of atherosclerosis, a leading cause of stroke and heart attack. Measures of blood vessel dilation give an indication of the health of the vessel. Ultrasound and MRI can assess vascular function by measuring changes in blood vessel dilation. Diabetes may also affect tiny vessels in the kidney. These vessels become porous allowing albumin (a protein in the blood) to leak into the urine. The investigators can easily measure the presence of albumin in the urine.

This study aims to explore if MRI can demonstrate an association between vascular health in tiny and larger (conduit) blood vessels, by testing for an association between blood flow regulatory capacity of large vessels and presence of albumin in the urine.

03

Conditions studied

  • Diabetes
  • Endothelial Dysfunction

Keywords

  • Flow mediated dilation
  • Magnetic Resonance Imaging MRI
  • Diabetes
  • Endothelial dysfunction
  • Popliteal artery
  • Atherosclerosis
  • Cardiovascular disease
  • Vascular disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men and women with type 2 diabetes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with type 2 diabetes who:

    • are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks
    • have diabetes diagnosed >6 months
    • have maintained stable weight for 2 months (within 3%)
    • have a valid Ontario Health Insurance Plan (OHIP) card and a family physician
    • if prescribed lipid medication, have taken a stable dose for at least 2 weeks
    • if prescribed blood pressure medication, have taken a stable dose for at least 1 week
    • can keep written food records
    • carotid intima-media thickness (cIMT) \< 1.2 mm and ankle brachial index (ABI) of >0.9.

Exclusion criteria

Exclusion Criteria:

  • Individuals who

    • take insulin
    • take
    • have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS)
    • have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months
    • take warfarin (Coumadin)
    • have had major surgery in the past 6 months
    • have a major debilitating disorder
    • have liver disease ( liver transaminase levels > 130 U/L), excluding Nonalcoholic fatty liver (NAFL) disease or NASH
    • have or C
    • have renal failure (high creatinine > 150 mmol/L)
    • have serum triglycerides ≥ 6.0 mmol/L
    • have a history of cancer, except non-melanoma skin cancer (basal cell, squamous cell)
    • have food allergies to study food components
    • have acute or chronic infections (bacterial or viral)
    • have chronic inflammatory diseases (e.g. rheumatoid arthritis, lupus; ulcerative colitis)
    • have other conditions which in the opinion of any of the investigators would make them unsuitable for the study
    • Any condition or circumstance which would prevent an individual from having an MRI (e.g. individuals with prostheses or metal implants, or those who are excessively claustrophobic)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease

    If this MRI technique is sensitive enough to demonstrate an association between flow mediated dilatation (FMD) of the popliteal artery and albuminuria, this will make a case for the use of the MRI technique in measuring effects of various interventions on vascular function.

    Time frame: One year

Secondary outcomes

  1. Blood measures related to cardiovascular disease and renal function

    Time frame: One year

  2. Dietary risk factors related to chronic disease

    Time frame: One year

07

Study locations

1 site
  • St Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jun 2014, a primary completion of Nov 2026 and a completion of Nov 2026. It does not say whether these dates are actual or estimated.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2015 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Aug 1, 2014
Start
Jun 2014
Primary completionEst.
Nov 2026was Nov 2015
CompletionActual
Nov 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn funding issue
changed Nov 19, 2026
Primary completion
Nov 2015→Nov 2026
Nov 19, 2026
Study completion
Set to Nov 2026 (actual)
Nov 19, 2026
Enrollment
60 (estimated)→0 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Status unknown→Withdrawn
    Why stopped funding issue
    Primary completion Nov 2015→Nov 2026
    Study completion Set to Nov 2026 (now actual)
    Enrollment 60 (estimated)→0 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02206919
Responsible party
Dr. Alan Moody (Staff physician, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Aug 1, 2014
Start date
Jun 2014
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026
Last update
Nov 19, 2026

Study contacts

Alan Moody, DR
principal investigator · Sunnybrook Health Sciences Centre
David Jenkins, DR
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion